PCSK9 inhibitors: emerging treatment to lower cholesterol?

Gencer, B; Rodondi, Nicolas; Mach, F (2014). PCSK9 inhibitors: emerging treatment to lower cholesterol? Revue médicale suisse, 10(420), pp. 539-542. Médecine & Hygiène

Full text not available from this repository. (Request a copy)

The achievement rate of recommended low-density lipoprotein cholesterol (LDL-C) targets of < 1.8 mmol/l for secondary prevention in very high risk patients is difficult. Observational studies reported that loss of function mutation of the PCS9 was associated with LDL-C decrease level and reduction of cardiovascular events. Monoclonal antibodies to PCSK9 (REGN727 and AMG 145, PSCK9 inhibitors) have been tested in clinical studies of phase I and II and showed LDL-C level reduction of 60-70% compared to placebo. This approach appears safe and well-tolerated. The PCSK9 inhibitors are now tested in large phase III clinical studies to assess the long-term safety and efficacy of this new promising approach.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Department of General Internal Medicine (DAIM) > Clinic of General Internal Medicine > Centre of Competence for General Internal Medicine

UniBE Contributor:

Rodondi, Nicolas

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0025-6749

Publisher:

Médecine & Hygiène

Language:

French

Submitter:

Patricia Rajaonina

Date Deposited:

07 Apr 2015 12:00

Last Modified:

23 Jun 2015 15:00

PubMed ID:

24701672

URI:

https://boris.unibe.ch/id/eprint/66231

Actions (login required)

Edit item Edit item
Provide Feedback